We hypothesized that antagonizing the IL-6 pathway in CHIP carriers will reduce their risk of cardiovascular disease (CVD) since CHIP speeds up atherosclerosis and elevates IL-6/IL-1 expression in mice [17]. The gene discussed is IL1B; the disease is atherosclerosis.